Brief: Celcuity To Initiate NDA Submission Of Gedatolisib In PIK3CA Wild-Type Cohort In HR+/HER2- Advanced Breast Cancer Under FDA’s Real-Time Oncology Review Program
27/08/2025 21:31
Aug 27 (Reuters) - Celcuity Inc CELC.O: CELCUITY TO INITIATE NDA SUBMISSION OF GEDATOLISIB IN PIK3CA WILD-TYPE COHORT IN HR+/HER2- ADVANCED BREAST CANCER UNDER FDA’S REAL-TIME ONCOLOGY REVIEW PROGRAM Source text: ID:nGNX2rZCzR Further company coverage: CELC.O ((Reuters.Briefs@thomsonreuters.com;))